Furthermore, overexpression of members of the Bcl-2 family of anti-apoptotic mediators has been associated with bortezomib resistance [15, 16] and it has been shown that the anti-tumour activity of bortezomib is enhanced by Bcl-2 antagonists [17–19]. This evidence concerns the gene BCL2 and neoplasm.